Molecular link between herpes and cancer

09.05.2009

Lisbon/New York - A Portuguese-US research team has discovered a new molecular mechanism that enables gamma herpes viruses to chronically infect patients. Gamma herpes viruses infect white blood cells (B- or T-lymphocytes) remaining latent in the lymphoid tissues as an asymptomatic chronic infection. The results of the study, which were published online in the EMBO Journal, offer a greater understanding of why these patients are more likely to suffer from lymphocyte (white blood cell) cancer lymphoma immunodeficiency.
The researchers' findings demonstrate that a protein from the gamma herpes viruses, called ORF73, mimics the host´s molecular machinery to inhibit NF-kB on infected lymphocytes. NF-kB is a protein complex that acts as a transcription factor and is involved in cellular responses to various stimuli including death and proliferation. The researchers pointed out that the viral manipulation of the host molecular machinery wreaks havoc with the normal controls of the cells, which, in turn, raises the risk of cancer. If NF-kB inhibition in gamma herpes virus-infected patients with lymphomas is confirmed, drugs capable of saving the molecule could maybe decrease the chances of someone developing lymphomas.
Participating in the study were the Institutes of Microbiology and of Molecular Medicine at the University of Lisbon (Portugal), the Gulbenkian Science Institute (Portugal) and the Weill Medical College of Cornell University (US).

PortugalPortugal

02.12.2011

Lisbon – Genetically modified organisms (GMOs) are gaining ground in southwestern Europe. According to the European Association for Bioindustries (EuropaBio), Portuguese farmers planted nearly 60% more genetically modified maize...

PortugalPortugal

07.10.2011

Lisbon – In the southwest of Europe, GMOs are gaining ground. According to the European Association for BioIndustries EuropaBio, Portuguese farmers have grown nearly 60% more genetically modified (GM) maize this year compared to...

PortugalPortugal

11.08.2011

Lisbon – According to a report published by business intelligence provider Espicom, the future for biopharma on the westernmost tip of Europe looks anything but sunny. Its analysts predict that by 2016, the pharmaceuticals market...

PortugalPortugal

08.03.2010

Lisbon – Portugal’s “Fundação para a Ciência e Tecnologia” (FCT) is to channel funding into collaborations between Portuguese and Indian life science companies and research within the networking pilot programme “New Indigo”...

PortugalPortugal

14.09.2009

Coimbra/San Francisco/Munster – Portuguese and US researchers have discovered a new factor that determines whether an embryonic stem cell (ESC) will remain pluripotent or not. After the team under Miguel and Joao Ramalho-Santos...

PortugalPortugal

12.07.2009

Madrid –The Spanish Ministry of Health is investing in future biotech treatments. In July, it signed a EUR60m contract over a recombinantly manufactured flu vaccine developed by Rockville-based Novavax. In Phase II trials, the...

PortugalPortugal

21.02.2009

Lisbon – Portugal’s Bial SA has granted American company Sepracor the exclusive rights to develop and commercialise eslicarbazepine in the United States and Canada. Bial will receive US$57m up front.

PortugalPortugal

03.11.2008

Poco Barreto – In mid-August, 60 anti-GMO activists destroyed a field planted with insect-resistant Mon810 maize in Portugal. Near the small Algarve town of Poco Barreto, activists from the “Movimento Verde Eufemia” trampled...

Displaying results 1 to 10 out of 37

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-portugal/article/molecular-link-between-herpes-and-cancer.html

Image Gallery

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR53.3%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-44.9%
  • PROTHENA PLC (IE)28.07 USD-40.8%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 19.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper